Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national
5
×
national blog main
national top stories
new york top stories
san francisco top stories
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
new york blog main
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
fda
gene therapy
novartis
roche
spark therapeutics
alnylam pharmaceuticals
amgen
amicus therapeutics
biogen
cancer
cystic fibrosis
deals
What
drug
5
×
patients
5
×
bio
fda
roundup
market
medicine
new
therapy
acquisitions
advantages
albert
approved
aren’t
atrophy
bar
biggest
bourla
brings
cancer
ceo
company
crispr
daily
developers
drugs
eisai
evrysdi
expect
flags
friday
future
gamble
gene
green
help
higher
home
imminent
imports
Language
unset
unknown
Current search:
drug
×
national
×
patients
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More